Alyeska Investment Group L.P. Has $124.27 Million Position in Kenvue Inc. (NYSE:KVUE)

Alyeska Investment Group L.P. boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 67.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,820,813 shares of the company's stock after acquiring an additional 2,337,926 shares during the quarter. Alyeska Investment Group L.P. owned approximately 0.30% of Kenvue worth $124,274,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Norges Bank bought a new position in shares of Kenvue in the fourth quarter valued at approximately $521,348,000. Franklin Resources Inc. lifted its position in Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after acquiring an additional 16,269,721 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Kenvue by 12.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after acquiring an additional 10,682,003 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Kenvue by 3.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock valued at $5,249,665,000 after purchasing an additional 8,211,748 shares during the last quarter. Finally, Boston Partners increased its stake in shares of Kenvue by 36.9% in the fourth quarter. Boston Partners now owns 23,595,963 shares of the company's stock worth $503,145,000 after purchasing an additional 6,366,097 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Canaccord Genuity Group increased their target price on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Piper Sandler upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Royal Bank of Canada restated a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Citigroup upped their price objective on shares of Kenvue from $21.00 to $22.00 and gave the company a "neutral" rating in a research report on Monday, April 14th. Finally, Barclays decreased their target price on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Monday, April 14th. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $24.42.

Kenvue Price Performance

KVUE stock traded down $0.35 during trading on Monday, hitting $23.63. The company had a trading volume of 23,279,545 shares, compared to its average volume of 17,062,863. The company has a fifty day moving average price of $23.10 and a two-hundred day moving average price of $22.53. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a market cap of $45.34 billion, a P/E ratio of 44.58, a P/E/G ratio of 2.62 and a beta of 1.02. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.47%. The ex-dividend date is Wednesday, May 14th. Kenvue's payout ratio is 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.